Skip to main content

Table 1 Demographic, clinical, and surgery-related characteristics of all patients

From: The impact of warfarin on operative delay and 1-year mortality in elderly patients with hip fracture: a retrospective observational study

  Warfarin Antiplatelet Control Total p value
Patient 157 (12%) 442 (34%) 693 (54%) 1292 (100%)  
Gender
 Male 59 (38%) 115 (26%) 159 (23%) 333 (26%) 0.001
 Female 98 (62%) 327 (74%) 534 (77%) 959 (74%)
Age, mean ± sd 84.76 ± 6.08 84.09 ± 6.61 83.69 ± 8.15 83.96 ± 7.42 0.3567
ASA score
 1/2 0 13 (3%) 69 (10%) 82 (7%) < 0.001
 3 34 (22%) 165 (38%) 350 (51%) 549 (43%)
 4/5 120 (78%) 256 (59%) 265 (39%) 641 (50%)
CCI, median (IQR, Q1 to Q3) 6 (5–7) 6 (4–7) 5 (4–6) 5 (4–7) 0.0001
AO/OTA Classification
 A1 42 (27%) 93 (21%) 139 (20%) 274 (21%) 0.47
 A2 34 (22%) 108 (25%) 164 (24%) 306 (24%)
 A3 7 (4%) 43 (10%) 65 (10%) 115 (9%)
 B1 20 (13%) 70 (16%) 112 (16%) 202 (16%)
 B2 43 (28%) 103 (23%) 168 (24%) 314 (24%)
 B3 10 (6%) 22 (5%) 43 (6%) 75 (6%)
Types of surgical procedure
 Reconstruction 63 (40%) 178 (40%) 282 (41%) 523 (40%) 0.986
 Fixation 94 (60%) 264 (60%) 411 (59%) 769 (60%)
Time to surgery
 < 48 h 72 (46%) 277 (63%) 479 (69%) 828 (64%) < 0.001
 > 48 h 85 (54%) 165 (37%) 214 (31%) 464 (36%)
Blood loss (ml)
 Median (IQR, Q1 to Q3) 964.04 (446.95–1652.62) 904.105 (454.4–1486.93) 864.3 (394.59–1349.29) 879.02 (419.33–1446.43) 0.0054
 0–490 ml 40 (26%) 119 (27%) 241 (35%) 400 (31%) 0.033
 491–980 ml 40 (26%) 139 (31%) 197 (28%) 376 (29%)
 981–1470 ml 30 (19%) 69 (16%) 96 (14%) 195 (15%)
 > 1471 ml 45 (29%) 115 (26%) 157 (23%) 317 (25%)
Mortality
 30 days 13 (8%) 14 (3%) 28 (4%) 55 (4%) 0.0484*
 180 days 42 (27%) 69 (16%) 100 (14%) 211 (16%) 0.0005*
 1 year 61 (39%) 109 (25%) 140 (20%) 310 (24%) < 0.0001*
  1. Note: *the p values related to mortality at 30 days, 180 days, and 1 year were calculated with the log-rank test